News & Updates
Filter by Specialty:

Are pregnant women with rheumatic disease at risk of poor COVID-19 outcomes?
Pregnant women with rheumatic disease and COVID-19 show favourable outcomes, but data are limited by the small sample size and methodology, reports a study.
Are pregnant women with rheumatic disease at risk of poor COVID-19 outcomes?
20 Jan 2022
Sitafloxacin a promising treatment alternative for UTI
Oral sitafloxacin was just as effective and safe as levofloxacin for the treatment of complicated and uncomplicated urinary tract infections (UTIs) in adults, according to a phase III study from China.
Sitafloxacin a promising treatment alternative for UTI
20 Jan 2022
Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.
Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
12 Jan 2022
Pyrotinib + capecitabine extends OS in metastatic breast cancer
Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.